Free Trial

Aberdeen Group plc Purchases 77,511 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Structure Therapeutics logo with Medical background

Key Points

  • Aberdeen Group plc increased its stake in Structure Therapeutics by 45.2%, acquiring an additional 77,511 shares, bringing its total holdings to 248,899 shares valued at approximately $4.3 million.
  • Institutional investors collectively own 91.78% of Structure Therapeutics, with notable increases from firms such as Deep Track Capital LP, which raised its position by 129.4% in the fourth quarter.
  • Recent analyst reports noted a downward adjustment in price targets for Structure Therapeutics, with JMP Securities lowering it from $89.00 to $87.00 while still maintaining a "market outperform" rating.
  • Five stocks to consider instead of Structure Therapeutics.

Aberdeen Group plc grew its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 45.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 248,899 shares of the company's stock after acquiring an additional 77,511 shares during the quarter. Aberdeen Group plc owned about 0.43% of Structure Therapeutics worth $4,308,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Invesco Ltd. boosted its holdings in shares of Structure Therapeutics by 6.1% during the 1st quarter. Invesco Ltd. now owns 394,386 shares of the company's stock valued at $6,827,000 after acquiring an additional 22,619 shares during the last quarter. National Bank of Canada FI boosted its holdings in shares of Structure Therapeutics by 1,448.2% during the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after acquiring an additional 2,766 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Structure Therapeutics by 310.7% during the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after acquiring an additional 3,213 shares during the last quarter. Readystate Asset Management LP boosted its holdings in shares of Structure Therapeutics by 129.9% during the 1st quarter. Readystate Asset Management LP now owns 481,241 shares of the company's stock valued at $8,330,000 after acquiring an additional 271,899 shares during the last quarter. Finally, Banque Pictet & Cie SA boosted its holdings in shares of Structure Therapeutics by 10.2% during the 1st quarter. Banque Pictet & Cie SA now owns 81,766 shares of the company's stock valued at $1,415,000 after acquiring an additional 7,589 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Analysts Set New Price Targets

GPCR has been the topic of a number of research reports. HC Wainwright dropped their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Cantor Fitzgerald reissued an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. JMP Securities dropped their price objective on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Citigroup initiated coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. Finally, Guggenheim dropped their price objective on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, According to MarketBeat, Structure Therapeutics has a consensus rating of "Buy" and a consensus price target of $75.71.

View Our Latest Report on GPCR

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock traded up $0.25 on Tuesday, hitting $18.82. 424,017 shares of the company traded hands, compared to its average volume of 900,051. The stock has a market capitalization of $1.08 billion, a P/E ratio of -17.92 and a beta of -1.89. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $13.22 and a 52 week high of $45.37. The business has a 50-day simple moving average of $19.16 and a 200 day simple moving average of $20.95.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). Research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

About Structure Therapeutics

(Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Further Reading

Institutional Ownership by Quarter for Structure Therapeutics (NASDAQ:GPCR)

Should You Invest $1,000 in Structure Therapeutics Right Now?

Before you consider Structure Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.

While Structure Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.